PE20020885A1 - Compuestos de quinazol como inhibidores de mmp - Google Patents

Compuestos de quinazol como inhibidores de mmp

Info

Publication number
PE20020885A1
PE20020885A1 PE2002000115A PE2002000115A PE20020885A1 PE 20020885 A1 PE20020885 A1 PE 20020885A1 PE 2002000115 A PE2002000115 A PE 2002000115A PE 2002000115 A PE2002000115 A PE 2002000115A PE 20020885 A1 PE20020885 A1 PE 20020885A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
compounds
benzyl
quinazole
Prior art date
Application number
PE2002000115A
Other languages
English (en)
Inventor
Charles Andrianjara
Henry Jacobelli
Bernard Gaudilliere
Francine Breuzard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20020885A1 publication Critical patent/PE20020885A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A QUINAZOLINAS DE FORMULA I DONDE W ES N, CR1; R1 ES H, OR5, SR5, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, ENTRE OTROS, X ES N, CR2; R2 ES H, NR6R7, OR6, ENTRE OTROS; R6 Y R7 SON H, ALQUILO C1-C6, ENTRE OTROS; Y ES O, S, NH, N-ALQUILO C1-C6; Z ES O, S, Y-NR8; R8 ES H, ALQUILO C1-C6, ARILO, ENTRE OTROS; Z ES UN ATOMO DE CARBONO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C6, ARILO, ENTRE OTROS; n ES 0-8; Z1 ES CR9R10; R9 Y R10 SON H, ALQUILO C1-C6, HALOGENO, NR5R11, ENTRE OTROS; R5 Y R11 SON H, ALQUILO C1-C6; A ES UN MONOCICLO, BICICLO AROMATICO O NO AROMATICO; m ES 0-7; R4 ES ALQUILO C1-C6, HALOGENO, CN, NO2, SCF3C, ENTRE OTROS; X1 ES O, S OPCIONALMENTE SUSTITUIDO O, N; k ES 0-3; R5 Y R11 SON H, ALQUILO C1-C6; X2 ES UN ENLACE, CH2, O, S; R12 ES UN HETEROCICLO, NO HETEROCICLO; R3 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, UN GRUPO a, ENTRE OTROS; p ES 0-8; Z2 ES CR14R15; R14 Y R15 SON H, ALQUILO C1-C6, FENILO, ENTRE OTROS; B ES MONOCICLO, BICICLO; q ES 0-7; R13 ES ALQUILO C1-C6, HALOGENO, CN, NO2, ENTRE OTROS; q ES 0-7; R13 ES ALQUILO C1-C6, HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS BENCIL 4-BENCIL-5-OXO-4H-[1,2,4]TRIAZOL[4,3-a]QUINAZOL-7-ILCARBOXILATO, 4-PIRIDILMETIL 4-BENCIL-5-OXO-4H-[1,2,4]TRIAZOL[4,3-a]QUINAZOL-ILCARBOXILATO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ARTRITIS, ARTRITIS REUMATICA, OSTEOARTRITIS, OSTEOPOROSIS
PE2002000115A 2001-02-14 2002-02-13 Compuestos de quinazol como inhibidores de mmp PE20020885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26875701P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
PE20020885A1 true PE20020885A1 (es) 2002-10-26

Family

ID=23024335

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000115A PE20020885A1 (es) 2001-02-14 2002-02-13 Compuestos de quinazol como inhibidores de mmp

Country Status (15)

Country Link
US (1) US6849637B2 (es)
EP (1) EP1362048B1 (es)
JP (1) JP2004521908A (es)
AR (1) AR032677A1 (es)
AT (1) ATE294805T1 (es)
BR (1) BR0207270A (es)
CA (1) CA2437588A1 (es)
DE (1) DE60203995T2 (es)
ES (1) ES2239216T3 (es)
HN (1) HN2002000038A (es)
MX (1) MXPA03007249A (es)
PA (1) PA8539501A1 (es)
PE (1) PE20020885A1 (es)
SV (1) SV2002000875A (es)
WO (1) WO2002064595A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207216A (pt) * 2001-02-14 2004-03-09 Warner Lambert Co Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
JP2006502992A (ja) * 2002-07-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ−１３のアロステリック阻害剤とセレコキシブ又はバルデコキシブとの組合せ
EP1534274A1 (en) * 2002-07-17 2005-06-01 Warner-Lambert Company LLC Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
WO2004006912A2 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
CA2492391A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
WO2004014867A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1537098A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003250471A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2004014869A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003250469A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Isoquinoline derivatives as matrix metalloproteinase inhibitors
WO2004014354A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
BR0313384A (pt) 2002-08-13 2005-07-12 Warner Lambert Co Derivados de cromona como inibidores de metaloproteinases de matriz
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
CA2572324A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US20060293345A1 (en) * 2005-05-20 2006-12-28 Christoph Steeneck Heterobicyclic metalloprotease inhibitors
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7795877B2 (en) * 2006-11-02 2010-09-14 Current Technologies, Llc Power line communication and power distribution parameter measurement system and method
WO2008063671A2 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204487C1 (en) 2008-01-04 2014-10-16 Intellikine, Llc Certain chemical entities, compositions and methods
DE102010031945A1 (de) * 2010-07-22 2012-01-26 Osram Opto Semiconductors Gmbh Halbleiterbauelement und Verfahren zur Herstellung eines Halbleiterbauelements
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN115197225B (zh) * 2021-09-03 2023-04-11 贵州大学 一种五元杂环并喹唑啉酮类化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
DE3677445D1 (de) * 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
IL128545A0 (en) 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
HN2000000137A (es) 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
EA200300409A1 (ru) 2000-10-26 2003-08-28 Пфайзер Продактс Инк. Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
OA12529A (en) 2000-10-26 2006-06-02 Pfizer Prod Inc Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors.
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
SV2003001289A (es) 2001-10-12 2003-06-24 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado
CA2462442A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
WO2003076416A1 (en) 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) * 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2002333256A1 (en) 2002-06-25 2004-01-06 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
WO2004014384A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
US6849637B2 (en) 2005-02-01
AR032677A1 (es) 2003-11-19
WO2002064595A1 (en) 2002-08-22
ES2239216T3 (es) 2005-09-16
ATE294805T1 (de) 2005-05-15
SV2002000875A (es) 2002-10-04
JP2004521908A (ja) 2004-07-22
BR0207270A (pt) 2004-02-10
US20020151558A1 (en) 2002-10-17
DE60203995T2 (de) 2005-09-22
PA8539501A1 (es) 2002-09-30
DE60203995D1 (de) 2005-06-09
MXPA03007249A (es) 2005-02-14
EP1362048A1 (en) 2003-11-19
CA2437588A1 (en) 2002-08-22
EP1362048B1 (en) 2005-05-04
HN2002000038A (es) 2002-09-05

Similar Documents

Publication Publication Date Title
PE20020885A1 (es) Compuestos de quinazol como inhibidores de mmp
PE20041000A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
DK1836201T3 (da) Pyrrolidininhibitorer af IAP
PE20020915A1 (es) Diaminotiazoles como inhibidores de quinasas dependientes de ciclina
ATE433981T1 (de) Heterocyclische verbindungen
EA200800873A1 (ru) Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы
PE20030010A1 (es) Triazolopiridinas como inhibidores de quinasas
PE20091371A1 (es) Inhibidores de hsp90
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
CY1107468T1 (el) Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχους
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
ECSP056131A (es) Compuestos de carbonilo
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
SV2003000162A (es) Los inhibidores triciclicos de poli (adp-ribosa) polimerasas
CY1111349T1 (el) Καρβαμιδικες ενωσεις προς χρηση στη θεραπεια του πονου
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
ECSP066632A (es) El uso de derivados de n-arilhidrazina para combatir pestes en y sobre animales
HK1053463A1 (en) Aminobenzophenones as inhibitors of il-1B and TNF-a.
DE60333746D1 (de) Thienylverbindungen
CY1105330T1 (el) Καρβαμιδικα παραγωγα για χρηση στην προληψη ή την αγωγη της διπολικης διαταραχης
DE60322224D1 (de) Kondensierte heterozyklische verbindungen als petidase inhibitoren
CY1107149T1 (el) Νεα παραγωγα αμιδινοβενζυλαμινης και χρηση τους ως αναστολεων θρομβινης
CY1111428T1 (el) Μεθοδος για τη συνθεση της 5-(μεθυλ-1η-ιμιδαζολ-1-υλο)-3-(τριφθορομεθυλο)-βενζολαμινης
PT1202957E (pt) Aminobenzofenonas como inibidoras de il-1beta e tnf-alpha

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed